Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Icu Medical (ICUI) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $607000.0.

  • Icu Medical's Non Operating Income rose 14098.58% to $607000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year increase of 2660.36%. This contributed to the annual value of -$13.2 million for FY2024, which is 12392.89% down from last year.
  • According to the latest figures from Q3 2025, Icu Medical's Non Operating Income is $607000.0, which was up 14098.58% from $1.8 million recorded in Q2 2025.
  • Icu Medical's 5-year Non Operating Income high stood at $1.8 million for Q2 2025, and its period low was -$6.0 million during Q4 2024.
  • For the 5-year period, Icu Medical's Non Operating Income averaged around -$1.3 million, with its median value being -$1.4 million (2022).
  • As far as peak fluctuations go, Icu Medical's Non Operating Income plummeted by 658555.56% in 2024, and later soared by 15372.34% in 2025.
  • Icu Medical's Non Operating Income (Quarter) stood at -$3.0 million in 2021, then soared by 61.07% to -$1.2 million in 2022, then soared by 92.19% to -$90000.0 in 2023, then tumbled by 6585.56% to -$6.0 million in 2024, then soared by 110.09% to $607000.0 in 2025.
  • Its Non Operating Income was $607000.0 in Q3 2025, compared to $1.8 million in Q2 2025 and -$1.8 million in Q1 2025.